ZLAB Zai Lab
- 20.840
- +1.440+7.42%
- 20.790
- -0.050-0.24%
Zai Lab News
J.P. Morgan sold 24.862 million common shares of Zaiding Pharmaceuticals (09688.HK) worth approximately HK$416 million
On May 20, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 20, JPMorgan Chase & Co. (JPMorgan Chase & Co.) sold $24.8812 million common shares worth approximately HK$416 million on May 13 at an average price of HK$16.7427 per share on the market and an average price of HK$16.7891 per share outside the market. After the sale, J.P. Morgan Chase's latest shareholding was 150 million shares, and the good position ratio dropped from 17.67% to 15.16%. Image source: Stock Exchange equity disclosure What is equity
J.P. Morgan sold 18.578,200 common shares of Zaiding Pharmaceuticals (09688.HK), worth approximately HK$313 million
On May 20, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 20, JPMorgan Chase & Co. (JPMorgan Chase & Co.) sold $18.578,200 common shares worth approximately HK$313 million on May 14 at an average price of HK$16.8221 per share and an average OTC price of HK$16.8121 per share. After the sale, J.P. Morgan Chase's latest shareholding was 132 million shares, and the good position ratio fell from 15.16% to 13.29%. Photo source: Stock Exchange share disclosure what is a right
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab (ZLAB) and Innoviva's (INVA) Specialty Therapeutics subsidiary said Monday China's National Medical Products Administration has approved Zai's new drug application for Xacduro, the two firms'
Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+
Zaiding Pharmaceutical (09688.HK): China Drug Administration approved Dingyule (sulbactam sodium-dulobactan sodium) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by sensitive isolates of Ba
Zaiding Pharmaceutical (09688.HK) announced that China's State Drug Administration has approved a new drug marketing application for Dingyule (sulbactan sodium-dulobactan sodium) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by sensitive isolates of Baumann-Calcium Acetate Acinetobacter complex in patients aged 18 and above.
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China >ZLAB
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter B
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO (sulbactam-durlobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.
Weekend Readings | Buffett's “mysterious” holdings are in Chubb Insurance, losing Munger's Daily Journal and starting to cut back...
This article analyzes 10 “investment giants” including Berkshire Hathaway, The Daily Journal, Gao Lin HLR, Jing Lin, Qiaoshui, Baillie Gifford, ARK, Fisher Price, and Pershing Plaza.
Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
Zai Lab(ZLAB.US) Officer Sells US$213.35K in Common Stock
$Zai Lab(ZLAB.US)$ Officer Edmondson Frazor Titus III sold 10,000 shares of common stock on May 14, 2024 at an average price of $21.3346 for a total value of $213.35K.Source: Announcement What is stat
Zaiding Pharmaceutical (09688.HK) received 19.513 million shares from J.P. Morgan
Glonghui, May 16 | According to the latest equity disclosure data on the Stock Exchange, on May 10, 2024, Zaiding Pharmaceutical (09688.HK) obtained JPMorgan Chase & Co. increased its holdings by 19.513 million shares at an average price of HK$15.9063 per share, involving approximately HK$310 million. After the increase in holdings, JPMorgan Chase & Co.'s latest number of open positions was 175,310,714 shares, and the holding ratio increased from 15.70% to 17.67%.
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
Asian equities traded in the US as American depositary receipts eased Thursday morning, declining 0.04% to 1,950.23 on the S&P Asia 50 ADR Index and paring earlier losses. From North Asia, the gainers
Zaiding Pharmaceutical (09688) granted a total of 50,400 share options and 37,400 restricted share units
Zaiding Pharmaceutical (09688) issued an announcement. On May 14, 2024 (EST), the company based on 2...
Zai Lab Announces Participation in May and June Investor Conferences
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that members of the Company's senior management team will participate in the following investor conferences in May and June 2024: J.P. Morgan 20th Annual
Zaiding Pharmaceutical (09688.HK) received 19.513,000 additional shares of common stock from J.P. Morgan Chase, worth approximately HK$310 million
On May 16, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 16, JPMorgan Chase & Co. (JPMorgan Chase & Co.) increased its common stock holdings of $15.9063 per share at an average price of HK$15.9063 per share and an average OTC share price of HK$16.3543 on May 10 by a total of HK$19.513 million. After the increase in holdings, J.P. Morgan Chase's latest shareholding was 175 million shares, and the good position ratio rose from 15.70% to 17.67%. Image source: Stock Exchange equity disclosure What is equity
Huatai Securities: Three Implications of MSCI China's Adjustment
Huatai Securities released a research report saying that in the early morning of May 15, MSCI's official website announced its semi-annual index adjustment results. Among them, the MSCI China Index included 8 A shares and 2 Hong Kong stocks, and excluded 41 A shares and 15 Hong Kong stocks. The adjustment results will take effect after closing on May 31. Three tips: 1) After reviewing the 13 rounds of adjustments since 21 years ago, the MSCI China A share adjustment may have a stable excess income window, and the incident effect of the semi-annual review is stronger, while Hong Kong stocks are regular or relatively weak due to the small extent of the adjustments. 2) Before and after the index adjustment came into effect, foreign capital (mainly passive foreign capital) flowed to China's equity market
The biotechnology sector of Hong Kong stocks weakened, with Zaiding Pharmaceuticals falling more than 6%, Pharmaceutical Kangde falling more than 5%, and Pharmaceutical Biotech and Zhaoyan New Pharmaceutical falling.
The biotechnology sector of Hong Kong stocks weakened, with Zaiding Pharmaceuticals falling more than 6%, Pharmaceutical Kangde falling more than 5%, and Pharmaceutical Biotech and Zhaoyan New Pharmaceutical falling.
The quarterly adjustment of the MSCI Index excludes 15 Hong Kong stocks. The effective date is scheduled for early June
① Which individual stocks will MSCI China adjust quarterly? ② How much impact does the MSCI Index have on the market?
Futu Morning Post | The three major US stock indices hit new highs! Ultramicrocomputers and Nvidia explode together
“New Federal Reserve News Agency”: The Federal Reserve may still not cut interest rates until September; “Big Short” Michael Burry took a heavy gold position in the first quarter.
Express News | Huatai Securities: MSCI China's A-share adjustments or a stable excess earnings window
Analysis
Price Target
No Data
